Overactive Bladder Treatment Guidelines

Introduction to Anticholinergic Agents

The European Association of Urology and other guideline societies do not recommend the concurrent use of multiple anticholinergic agents for overactive bladder, as it may increase the risk of anticholinergic side effects 1, 2
Oxybutynin has a higher discontinuation rate due to adverse effects compared to tolterodine, with a number needed to harm (NNTH) of 14 1

Tolterodine has a better side effect profile compared to oxybutynin, with dry mouth and insomnia occurring less frequently with tolterodine than oxybutynin (strength of evidence: high) 1
Compared to fesoterodine, dry mouth and headache are less common with tolterodine, and discontinuation due to adverse effects is lower with tolterodine (strength of evidence: moderate) 1
Oxybutynin has significantly higher discontinuation rates compared to tolterodine, which has discontinuation rates similar to placebo 1

No clinical guidelines recommend the concurrent use of multiple anticholinergic agents for overactive bladder, emphasizing the importance of using one agent at a time 1, 2
The European Association of Urology recommends tolterodine as a first-line treatment option due to its favorable side effect profile (strength of evidence: high) 1
The American College of Physicians notes that tolterodine has discontinuation rates due to adverse effects similar to placebo, according to high-quality evidence (strength of evidence: high) 1
The American Geriatrics Society notes that approximately 7% of patients treated with tolterodine 2mg twice daily discontinue treatment due to adverse events, comparable to 6% with placebo (strength of evidence: moderate) 1

The American College of Cardiology recommends that patients with a history of QT prolongation or those taking medications that prolong QT interval should use tolterodine with caution (strength of evidence: low) 1
The National Institute on Aging advises that elderly patients may be more susceptible to cognitive effects and confusion when taking tolterodine (strength of evidence: moderate) 1
The American Academy of Family Physicians suggests that dosage adjustment is recommended in patients with hepatic impairment, as metabolism is reduced, leading to higher blood levels and potentially more side effects (strength of evidence: moderate) 1
The European Medicines Agency warns that CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase tolterodine levels, requiring dosage reduction (strength of evidence: high) 1
The American Society of Clinical Pharmacology notes that CYP2D6 inhibitors may affect metabolism of tolterodine, and cholinesterase inhibitors may worsen dementia symptoms when used concurrently (strength of evidence: moderate) 1

The American Urological Association recommends monitoring for signs of urinary retention, especially in patients with bladder outlet obstruction (strength of evidence: moderate) 1
The International Continence Society advises being alert for cognitive changes, especially in elderly patients, and managing dry mouth with adequate hydration, sugar-free gum/candy, or saliva substitutes (strength of evidence: moderate) 1
The National Institute on Aging suggests considering dose reduction if side effects are troublesome but the medication is effective, and discontinuing medication if serious adverse effects occur (strength of evidence: moderate) 1